EMA Withdrawn: Libertek (roflumilast) — AstraZeneca AB

View source ↗

Summary

Libertek (roflumilast) has been withdrawn from the market by AstraZeneca AB.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Obstructive Pulmonary Disease

Drugs mentioned

• Libertek (roflumilast)

Snippet

Status: Withdrawn. Therapeutic area: Pulmonary Disease, Chronic Obstructive. MAH: AstraZeneca AB. Decision date: 11/01/2018